ResMed Inc. insider trading
RMDfinancial statementsForm 4 filings on EDGAR183 transactions since Nov 1, 2024
From August 4, 2026 to November 1, 2026, 0 insiders at ResMed Inc. bought $0 of stock in the open market, and 3 sold $5M. Officers and directors accounted for $0 of purchases and $5M of sales. The last reported transaction was an open-market sale by Rider Michael J on October 23, 2026.
The answer card and chart use the same period. Change the range above the chart to update both. Form 4 filings through October 26, 2026; awards, option exercises, tax withholding and gifts are excluded from these totals.
Stock price and insider activity
Daily price candles with insider purchases and sales directly beneath them on the same timeline. Bars show individual days; totals sum all days in the selected period.
Bought $0Sold $5MAug 4, 2026 – Nov 1, 2026
purchases above zero; sales below. Both use the transaction date and the same dollar scale. Hover, tap, or use arrow keys to inspect a date. Awards, exercises, tax withholding and gifts are excluded.
Dates with prices or insider activity are spaced evenly; empty weekends and holidays are omitted. Prices through Oct 30, 2026. Insider data through Nov 1, 2026. Prices are adjusted for splits; transaction values are reported dollars.
Every transaction
183 transactions from November 1, 2024 to November 1, 2026, newest first. Open-market purchases and sales are coloured; awards, exercises, tax withholding and gifts are grey and not counted.
| Traded | Insider | Role | Transaction | Shares | Price | Value | Held after | Filed |
|---|---|---|---|---|---|---|---|---|
| Oct 23, 2026 | Rider Michael J | Global General Counsel | open-market sale10b5-1 | 400 | $255.00 | $102K | 12,318 | Oct 26, 2026 |
| Oct 7, 2026 | Farrell Michael J. | Chairman and CEO, Director | option exercise | 4,991 | $146.34 | $730K | 484,794 | Oct 8, 2026 |
| Oct 7, 2026 | Farrell Michael J. | Chairman and CEO, Director | open-market sale10b5-1 | 4,991 | $226.33 | $1M | 479,803 | Oct 8, 2026 |
| Sep 8, 2026 | Farrell Michael J. | Chairman and CEO, Director | option exercise | 4,991 | $146.34 | $730K | 471,247 | Sep 10, 2026 |
| Sep 8, 2026 | Farrell Michael J. | Chairman and CEO, Director | open-market sale10b5-1 | 4,991 | $222.44 | $1M | 466,256 | Sep 10, 2026 |
| Sep 2, 2026 | Farrell Peter C | Director | open-market sale10b5-1 | 970 | $234.73 | $228K | 51,803 | Sep 4, 2026 |
| Aug 14, 2026 | Leong Justin | Chief Product Officer | award | 6,461 | $0.00 | — | 35,489 | Oct 1, 2026 |
| Aug 14, 2026 | Rider Michael J | Global General Counsel | award | 3,230 | $0.00 | — | 12,718 | Oct 1, 2026 |
| Aug 14, 2026 | Farrell Michael J. | Chairman and CEO, Director | award | 13,547 | $0.00 | — | 479,803 | Oct 1, 2026 |
| Aug 14, 2026 | Bloomer Aaron | Chief Financial Officer | award | 9,072 | $0.00 | — | 9,072 | Oct 1, 2026 |
| Aug 7, 2026 | Farrell Michael J. | Chairman and CEO, Director | option exercise | 4,991 | $146.34 | $730K | 471,247 | Aug 11, 2026 |
| Aug 7, 2026 | Farrell Michael J. | Chairman and CEO, Director | open-market sale10b5-1 | 4,991 | $205.69 | $1M | 466,256 | Aug 11, 2026 |
| Aug 5, 2026 | Farrell Peter C | Director | open-market sale10b5-1 | 8,000 | $225.00 | $2M | 52,773 | Aug 6, 2026 |
| Jul 7, 2026 | Farrell Michael J. | Chairman and CEO, Director | option exercise | 4,991 | $146.34 | $730K | 471,214 | Jul 9, 2026 |
| Jul 7, 2026 | Farrell Michael J. | Chairman and CEO, Director | open-market sale10b5-1 | 4,991 | $218.55 | $1M | 466,223 | Jul 9, 2026 |
| Jun 8, 2026 | Farrell Michael J. | Chairman and CEO, Director | option exercise | 4,991 | $146.34 | $730K | 471,214 | Jun 9, 2026 |
| Jun 8, 2026 | Farrell Michael J. | Chairman and CEO, Director | open-market sale10b5-1 | 4,991 | $193.96 | $968K | 466,256 | Jun 9, 2026 |
| Jun 1, 2026 | Rider Michael J | Global General Counsel | tax withholding | 269 | $190.57 | $51K | 9,488 | Jun 3, 2026 |
| May 7, 2026 | Farrell Michael J. | Chairman and CEO, Director | option exercise | 4,991 | $146.34 | $730K | 471,214 | May 11, 2026 |
| May 7, 2026 | Farrell Michael J. | Chairman and CEO, Director | open-market sale10b5-1 | 4,991 | $207.82 | $1M | 466,223 | May 11, 2026 |
| Apr 7, 2026 | Farrell Michael J. | Chairman and CEO, Director | option exercise | 4,991 | $146.34 | $730K | 471,214 | Apr 9, 2026 |
| Apr 7, 2026 | Farrell Michael J. | Chairman and CEO, Director | open-market sale10b5-1 | 4,991 | $225.50 | $1M | 466,223 | Apr 9, 2026 |
| Apr 1, 2026 | Sandercock Brett | Chief Financial Officer | open-market sale10b5-1 | 1,000 | $224.31 | $224K | 83,495 | Apr 3, 2026 |
| Apr 1, 2026 | Farrell Peter C | Director | open-market sale10b5-1 | 2,000 | $225.00 | $450K | 60,773 | Apr 2, 2026 |
| Mar 9, 2026 | Farrell Michael J. | Chairman and CEO, Director | option exercise | 4,991 | $146.34 | $730K | 471,214 | Mar 11, 2026 |
| Mar 9, 2026 | Farrell Michael J. | Chairman and CEO, Director | open-market sale10b5-1 | 4,991 | $251.03 | $1M | 466,223 | Mar 11, 2026 |
| Mar 4, 2026 | Farrell Peter C | Director | open-market sale10b5-1 | 2,000 | $260.22 | $520K | 62,773 | Mar 5, 2026 |
| Mar 2, 2026 | Sandercock Brett | Chief Financial Officer | open-market sale10b5-1 | 1,000 | $254.30 | $254K | 84,495 | Mar 3, 2026 |
| Feb 9, 2026 | Farrell Michael J. | Chairman and CEO, Director | option exercise | 4,991 | $146.34 | $730K | 471,214 | Feb 10, 2026 |
| Feb 9, 2026 | Farrell Michael J. | Chairman and CEO, Director | open-market sale10b5-1 | 4,991 | $273.78 | $1M | 466,223 | Feb 10, 2026 |
| Feb 4, 2026 | Farrell Peter C | Director | open-market sale10b5-1 | 2,000 | $251.31 | $503K | 64,773 | Feb 6, 2026 |
| Feb 4, 2026 | Rider Michael J | Global General Counsel | open-market sale10b5-1 | 50 | $260.00 | $13K | 9,691 | Feb 6, 2026 |
| Feb 2, 2026 | Sandercock Brett | Chief Financial Officer | open-market sale10b5-1 | 1,000 | $257.03 | $257K | 85,495 | Feb 3, 2026 |
| Jan 7, 2026 | Farrell Peter C | Director | open-market sale10b5-1 | 2,000 | $248.83 | $498K | 66,773 | Jan 9, 2026 |
| Jan 7, 2026 | Farrell Michael J. | Chairman and CEO, Director | open-market sale10b5-1 | 4,991 | $248.46 | $1M | 466,223 | Jan 8, 2026 |
| Jan 7, 2026 | Farrell Michael J. | Chairman and CEO, Director | option exercise | 4,991 | $146.34 | $730K | 471,214 | Jan 8, 2026 |
| Jan 2, 2026 | Sandercock Brett | Chief Financial Officer | open-market sale10b5-1 | 1,000 | $241.75 | $242K | 86,495 | Jan 5, 2026 |
| Jan 2, 2026 | Rider Michael J | Global General Counsel | open-market sale10b5-1 | 50 | $241.75 | $12K | 9,741 | Jan 5, 2026 |
| Dec 8, 2025 | Farrell Michael J. | Chairman and CEO, Director | option exercise | 4,991 | $146.34 | $730K | 471,214 | Dec 9, 2025 |
| Dec 8, 2025 | Farrell Michael J. | Chairman and CEO, Director | open-market sale10b5-1 | 4,991 | $251.41 | $1M | 466,223 | Dec 9, 2025 |
| Dec 3, 2025 | Farrell Peter C | Director | open-market sale10b5-1 | 2,000 | $251.47 | $503K | 68,773 | Dec 4, 2025 |
| Dec 1, 2025 | Rider Michael J | Global General Counsel | open-market sale10b5-1 | 50 | $244.16 | $12K | 9,791 | Dec 2, 2025 |
| Dec 1, 2025 | Sandercock Brett | Chief Financial Officer | open-market sale10b5-1 | 1,000 | $244.16 | $244K | 87,495 | Dec 2, 2025 |
| Nov 25, 2025 | De Witte Jan | Director | open-market sale10b5-1 | 2,055 | $255.00 | $524K | 4,261 | Nov 26, 2025 |
| Nov 20, 2025 | Leong Justin | Chief Product Officer | award | 1,848 | $0.00 | — | 29,028 | Nov 24, 2025 |
| Nov 20, 2025 | Hernandez John | Director | award | 1,073 | $0.00 | — | 5,118 | Nov 24, 2025 |
| Nov 20, 2025 | Mowad-Nassar Nicole | Director | award | 536 | $0.00 | — | 777 | Nov 24, 2025 |
| Nov 20, 2025 | Tan Desney | Director | award | 1,073 | $0.00 | — | 6,002 | Nov 24, 2025 |
| Nov 20, 2025 | Gill Harjit | Director | award | 1,073 | $0.00 | — | 10,940 | Nov 24, 2025 |
| Nov 20, 2025 | Drexler Karen | Director | award | 1,073 | $0.00 | — | 10,602 | Nov 24, 2025 |
Who the insiders are
Everyone who reported a transaction since November 1, 2024, by open-market value over twelve months. Shares held are after the insider’s latest directly held transaction.
| Insider | Role | Last transaction | Kind | Shares held | Bought, 12 months | Sold, 12 months | Sales under a plan |
|---|---|---|---|---|---|---|---|
| Farrell Michael J. | Chairman and CEO, Director | Oct 7, 2026 | option exercise | 484,794 | — | $15M (12) | 12 of 12 |
| Farrell Peter C | Director | Sep 2, 2026 | open-market sale | 51,803 | — | $5M (8) | 8 of 8 |
| Sandercock Brett | Chief Financial Officer | Apr 1, 2026 | open-market sale | 83,495 | — | $2M (6) | 6 of 6 |
| De Witte Jan | Director | Nov 25, 2025 | open-market sale | 4,261 | — | $646K (2) | 2 of 2 |
| Rider Michael J | Global General Counsel | Oct 23, 2026 | open-market sale | 12,318 | — | $139K (4) | 4 of 4 |
| Ghoshal Kaushik | Chief Commercial Officer, SaaS | Mar 10, 2025 | option exercise | 13,588 | — | — | — |
| Leong Justin | Chief Product Officer | Aug 14, 2026 | award | 35,489 | — | — | — |
| Hernandez John | Director | Nov 20, 2025 | award | 5,118 | — | — | — |
| Gill Harjit | Director | Nov 20, 2025 | award | 10,940 | — | — | — |
| Mowad-Nassar Nicole | Director | Nov 20, 2025 | award | 777 | — | — | — |
| Tan Desney | Director | Nov 20, 2025 | award | 6,002 | — | — | — |
| Drexler Karen | Director | Nov 20, 2025 | award | 10,602 | — | — | — |
| Burt Carol | Director | Nov 20, 2025 | award | 2,156 | — | — | — |
| Taylor Ronald R | Director | Nov 20, 2025 | award | 24,771 | — | — | — |
| DelOrefice Christopher | Director | Nov 20, 2025 | award | 2,423 | — | — | — |
| Bloomer Aaron | Chief Financial Officer | Aug 14, 2026 | award | 9,072 | — | — | — |
| Sulpizio Richard | Director | Nov 20, 2024 | award | 17,796 | — | — | — |
Questions
Are ResMed Inc. insiders buying or selling?
Over the twelve months to November 1, 2026, 5 insiders at ResMed Inc. sold $22M of stock in the open market, all by officers and directors, and no insider bought. Net, insiders sold $22M. Only open-market purchases and sales are counted.
Who sold the most ResMed Inc. stock in the last year?
Farrell Michael J. (Chairman and CEO, Director) sold $15M in 12 open-market sales over the twelve months to November 1, 2026.
Do ResMed Inc. executives sell under 10b5-1 plans?
32 of the 32 open-market sales in the last twelve months (100%) were reported as made under a Rule 10b5-1 trading plan, set up in advance. A sale under a plan is still counted as a sale.
What counts as insider buying here?
Only open-market purchases (Form 4 code P) and sales (code S) by officers, directors and 10% owners. Stock awards, option exercises, shares withheld for tax and gifts are listed in the table but never counted as buying or selling.
More on ResMed Inc.
- ResMed Inc. financial statements
- Insider buying and selling across all companies
- These transactions as JSON
From Form 4, 4/A and 5 filings with the SEC. A record of insider transactions, not a recommendation.